Form 4: Crescent Biopharma Director Receives Stock Option Grant

Director David Charles Lubner was granted 11,050 stock options in Crescent Biopharma, Inc. as part of his compensation.

Summary

• Director David Charles Lubner received a grant of 11,050 stock options on June 2, 2026.
• The options have an exercise price of $17.01 per share.
• The options are set to expire on June 2, 2036.
• Vesting occurs in full on the earlier of June 2, 2027, or the date of the next annual shareholder meeting, contingent on continued service.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a routine administrative filing regarding director compensation, which is neutral for the stock price.

Positives

• Aligns director interests with long-term shareholder value through equity-based compensation.

Negatives

• Results in potential future dilution for existing shareholders upon exercise of the options.

Risks

• Vesting is subject to the director's continued service to the company.

Future Outlook

The options vest in one year, signaling a commitment to the company's performance through at least the next annual meeting cycle.

Industry Context

StockSavvy.ai notes that equity grants to directors are standard practice in the biopharmaceutical sector to ensure leadership alignment with long-term clinical and commercial milestones.

Comparison to Industry Standards

• The grant size and vesting schedule are consistent with typical director compensation packages for small-cap biotech firms.
• The use of a one-year cliff vesting period is standard for board-level equity incentives.

Stakeholder Impact

• Shareholders may experience minor dilution if options are exercised in the future.

Next Steps

• Director to continue service to trigger vesting on June 2, 2027.

Key Dates

Keywords

Crescent Biopharma, CBIO, Form 4, Insider Trading, Stock Options, Director Compensation